Time-course of nigrostriatal neurodegeneration and neuroinflammation in the 6-hydroxydopamine-induced axonal and terminal lesion models of Parkinson's disease in the rat

Akiyama, 1989, Microglial response to 6-hydroxydopamine-induced substantia nigra lesions, Brain Res, 489, 247, 10.1016/0006-8993(89)90857-3 Ambrosi, 2010, Effects of early and delayed treatment with an mGluR5 antagonist on motor impairment, nigrostriatal damage and neuroinflammation in a rodent model of Parkinson's disease, Brain Res Bull, 82, 29, 10.1016/j.brainresbull.2010.01.011 Blandini, 2007, Time-course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6-hydroxydopamine in the rat: new clues from an old model, Eur J Neurosci, 25, 397, 10.1111/j.1460-9568.2006.05285.x Butovsky, 2005, Activation of microglia by aggregated beta-amyloid or lipopolysaccharide impairs MHC-II expression and renders them cytotoxic whereas IFN-gamma and IL-4 render them protective, Mol Cell Neurosci, 29, 381, 10.1016/j.mcn.2005.03.005 Chung, 2010, The role of neuroinflammation on the pathogenesis of Parkinson's disease, BMB Reproduction, 43, 225, 10.5483/BMBRep.2010.43.4.225 Cicchetti, 2002, Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging, Eur J Neurosci, 15, 991, 10.1046/j.1460-9568.2002.01938.x Counelis, 2003, Bilateral subthalamic nucleus deep brain stimulation for advanced PD: correlation of intraoperative MER and postoperative MRI with neuropathological findings, Mov Disord, 18, 1062, 10.1002/mds.10489 Crotty, 2008, Neuroprotective effects of novel phosphatidylglycerol-based phospholipids in the 6-hydroxydopamine model of Parkinson's disease, Eur J Neurosci, 27, 294, 10.1111/j.1460-9568.2007.06018.x Depino, 2003, Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease, Eur J Neurosci, 18, 2731, 10.1111/j.1460-9568.2003.03014.x DiLorenzo, 2010, Long-term deep brain stimulation for essential tremor: 12-year clinicopathologic follow-up, Mov Disord, 25, 232, 10.1002/mds.22935 Floden, 2005, Beta-amyloid-stimulated microglia induce neuron death via synergistic stimulation of tumor necrosis factor alpha and NMDA receptors, J Neurosci, 25, 2566, 10.1523/JNEUROSCI.4998-04.2005 Gaig, 2009, When does Parkinson's disease begin?, Mov Disord, 24, S656, 10.1002/mds.22672 Gao, 2008, Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression, Trends Immunol, 29, 357, 10.1016/j.it.2008.05.002 Gao, 2002, Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease, J Neurochem, 81, 1285, 10.1046/j.1471-4159.2002.00928.x Garden, 2006, Microglia biology in health and disease, J Neuroimmune Pharmacol, 1, 127, 10.1007/s11481-006-9015-5 Graeber, 1988, Axotomy of the rat facial nerve leads to increased CR3 complement receptor expression by activated microglial cells, J Neurosci Res, 21, 18, 10.1002/jnr.490210104 Grealish, 2008, Unilateral axonal or terminal injection of 6-hydroxydopamine causes rapid-onset nigrostriatal degeneration and contralateral motor impairments in the rat, Brain Res Bull, 77, 312, 10.1016/j.brainresbull.2008.08.018 He, 2001, Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum, Brain Res, 909, 187, 10.1016/S0006-8993(01)02681-6 Henderson, 2002, Postmortem analysis of bilateral subthalamic electrode implants in Parkinson's disease, Mov Disord, 17, 133, 10.1002/mds.1261 Henning, 2008, Differential astroglial activation in 6-hydroxydopamine models of Parkinson's disease, Neurosci Res, 62, 246, 10.1016/j.neures.2008.09.001 Hirsch, 2009, Neuroinflammation in Parkinson's disease: a target for neuroprotection?, Lancet Neurol, 8, 382, 10.1016/S1474-4422(09)70062-6 Iczkiewicz, 2007, Osteopontin expression in activated glial cells following mechanical- or toxin-induced nigral dopaminergic cell loss, Exp Neurol, 207, 95, 10.1016/j.expneurol.2007.05.030 Jarraya, 2003, Parkinson's disease, subthalamic stimulation, and selection of candidates: a pathological study, Mov Disord, 18, 1517, 10.1002/mds.10607 Kim, 2007, A pivotal role of matrix metalloproteinase-3 activity in dopaminergic neuronal degeneration via microglial activation, FASEB J, 21, 179, 10.1096/fj.06-5865com Koprich, 2008, Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease, J Neuroinflammation, 5, 8, 10.1186/1742-2094-5-8 Langston, 1999, Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure, Ann Neurol, 46, 598, 10.1002/1531-8249(199910)46:4<598::AID-ANA7>3.0.CO;2-F Lu, 2010, Novel anti-inflammatory and neuroprotective agents for Parkinson's disease, CNS Neurol Disord Drug Targets, 9, 232, 10.2174/187152710791012035 Marinova-Mutafchieva, 2009, Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6-hydroxydopamine model of Parkinson's disease, J Neurochem, 110, 966, 10.1111/j.1471-4159.2009.06189.x McGeer, 1988, Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains, Neurology, 38, 1285, 10.1212/WNL.38.8.1285 McGeer, 2003, Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration, Ann Neurol, 54, 599, 10.1002/ana.10728 Nussbaum, 2003, Alzheimer's disease and Parkinson's disease, N Engl J Med, 348, 1356, 10.1056/NEJM2003ra020003 Rodrigues, 2001, Astroglial and microglial reaction after a partial nigrostriatal degeneration induced by the striatal injection of different doses of 6-hydroxydopamine, Int J Neurosci, 109, 91, 10.3109/00207450108986528 Rodrigues, 2004, Astroglial and microglial activation in the Wistar rat ventral tegmental area after a single striatal injection of 6-hydroxydopamine, Int J Neurosci, 114, 197, 10.1080/00207450490249338 Rodriguez-Pallares, 2007, Mechanism of 6-hydroxydopamine neurotoxicity: the role of NADPH oxidase and microglial activation in 6-hydroxydopamine-induced degeneration of dopaminergic neurons, J Neurochem, 103, 145 Rosenblad, 2000, Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model, Exp Neurol, 161, 503, 10.1006/exnr.1999.7296 Sanchez-Pernaute, 2004, Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease, J Neuroinflammation, 1, 6, 10.1186/1742-2094-1-6 Sun, 2008, Postmortem analysis following 71 months of deep brain stimulation of the subthalamic nucleus for Parkinson disease, J Neurosurg, 109, 325, 10.3171/JNS/2008/109/8/0325 Tansey, 2008, Neuroinflammation in Parkinson's disease: is there sufficient evidence for mechanism-based interventional therapy?, Front Biosci, 13, 709, 10.2741/2713 Whitton, 2010, Neuroinflammation and the prospects for anti-inflammatory treatment of Parkinson's disease, Curr Opin Investig Drugs, 11, 788 Wu, 2002, Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease, J Neurosci, 22, 1763, 10.1523/JNEUROSCI.22-05-01763.2002 Zecca, 2003, Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics, Trends Neurosci, 26, 578, 10.1016/j.tins.2003.08.009 Zhang, 2007, Microglial PHOX and Mac-1 are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant alpha-synuclein, Glia, 55, 1178, 10.1002/glia.20532 Zhang, 2005, Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease, FASEB J, 19, 533, 10.1096/fj.04-2751com Zhang, 2004, Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase, FASEB J, 18, 589, 10.1096/fj.03-0983fje